[HTML][HTML] Decoding Oncofusions: Unveiling Mechanisms, Clinical Impact, and Prospects for Personalized Cancer Therapies
K Salokas, G Dashi, M Varjosalo - Cancers, 2023 - mdpi.com
Simple Summary Oncofusions, or cancer-associated fusion mutations, are driving forces in
cancer development. Advanced sequencing technologies have revolutionized their …
cancer development. Advanced sequencing technologies have revolutionized their …
CD74–ROS1 L2026M mutant enhances autophagy through the MEK/ERK pathway to promote invasion, metastasis and crizotinib resistance in non‐small cell lung …
X Xu, Y Li, R Xu, Y Meng, Z Li, D Zuo… - The FEBS Journal, 2024 - Wiley Online Library
The treatment of non‐small cell lung cancer (NSCLC) patients harboring a proto‐oncogene
tyrosine‐protein kinase c‐ros oncogene 1 (ROS1) fusion gene has greatly benefited from …
tyrosine‐protein kinase c‐ros oncogene 1 (ROS1) fusion gene has greatly benefited from …
Ros1 alterations as a potential driver of gliomas in infant, pediatric, and adult patients
DM Meredith, LD Cooley, A Dubuc, J Morrissette… - Modern Pathology, 2023 - Elsevier
Gliomas harboring oncogenic ROS1 alterations are uncommon and primarily described in
infants. Our goal was to characterize the clinicopathological features and molecular …
infants. Our goal was to characterize the clinicopathological features and molecular …
[HTML][HTML] TPR is a prognostic biomarker and potential therapeutic target associated with immune infiltration in hepatocellular carcinoma
T Long, W Wu, X Wang, M Chen - Molecular and …, 2024 - … .spandidos-publications.com
Liver cancer is the fourth leading cause of cancer‑related mortality worldwide and
hepatocellular carcinoma (HCC) is the most common primary liver cancer. In the present …
hepatocellular carcinoma (HCC) is the most common primary liver cancer. In the present …
[HTML][HTML] Advancements in NSCLC: From Pathophysiological Insights to Targeted Treatments
J Xu, L Tian, W Qi, Q Lv, T Wang - American Journal of Clinical …, 2024 - journals.lww.com
With the global incidence of non-small cell lung cancer (NSCLC) on the rise, the
development of innovative treatment strategies is increasingly vital. This review underscores …
development of innovative treatment strategies is increasingly vital. This review underscores …